Answers are grounded in this paper and cite their sources.
Briakinumab performed relatively stable under efficacy and safety outcome. Infliximab can be a good choice for its lower risk of infection. Brodalumab present very good potential in efficacy outcome like PASI and PGA. More clinical trials are required to supply more data about discontinuation of infliximab and infection of brodalumab and larger RCT for assessment of briakinumab.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: